拉丁美洲
医学
实体瘤
融合基因
基因
内科学
肿瘤科
家庭医学
癌症
遗传学
生物
政治学
法学
作者
Mauricio Cuello,Hernán Garcı́a Rivello,Fuad Huamán‐Garaicoa,Paulina Irigoyen-Piñeiros,César Lara-Torres,Manglio Rizzo,Miguel Ticona-Castro,R. Trejo,Pablo Zoroquiaín
出处
期刊:Future Oncology
[Future Medicine]
日期:2023-12-01
卷期号:19 (40): 2669-2682
被引量:1
标识
DOI:10.2217/fon-2023-0552
摘要
NTRK gene fusions have been detected in more than 25 types of tumors and their prevalence is approximately 0.3% in solid tumors. This low prevalence makes identifying patients who could benefit from TRK inhibitors a considerable challenge. Furthermore, while numerous papers on the evaluation of NTRK fusion genes are available, not all countries have guidelines that are suitable for their setting, as is the case with Latin America. Therefore, a group of oncologists and pathologists from several countries in Latin America (Argentina, Chile, Ecuador, Mexico, Peru and Uruguay) met to discuss and reach consensus on how to identify patients with NTRK gene fusions in solid tumors. To do so, they developed a practical algorithm, considering their specific situation and limitations.
科研通智能强力驱动
Strongly Powered by AbleSci AI